Södertälje is currently home to AstraZeneca’s largest global manufacturing facility, employing around 3,500. From the two big production sites located here we handle the whole process, from the chemical production of active pharmaceutical ingredients, to formulation, filling/tabletting, packing and providing them to our customers. Our production teams collaborate with academic as well as industry partners in Sweden and abroad, among them The Royal Institute of Technology (KTH) and Scania.
The medicines delivered from Sweden Operations account for approximately 35% of AstraZeneca’s total sales value.
We’re also currently investing around $299million in a new high-tech facility for manufacturing of biological medicines. By locating the new manufacturing plant here, we will combine our expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit.
Södertälje is also the headquarters of AstraZeneca’s Nordic-Baltic marketing company, and also hosts a number of global enabling functions. In total the site in Södertälje has 4,100 employees.